Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more
Botanix Pharmaceuticals Limited (BXPHF) - Net Assets
Latest net assets as of June 2025: $81.30 Million USD
Based on the latest financial reports, Botanix Pharmaceuticals Limited (BXPHF) has net assets worth $81.30 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($129.10 Million) and total liabilities ($47.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $81.30 Million |
| % of Total Assets | 62.98% |
| Annual Growth Rate | 5.4% |
| 5-Year Change | 290.86% |
| 10-Year Change | 2455.84% |
| Growth Volatility | 658.2 |
Botanix Pharmaceuticals Limited - Net Assets Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Botanix Pharmaceuticals Limited (1989–2025)
The table below shows the annual net assets of Botanix Pharmaceuticals Limited from 1989 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $81.30 Million | -25.23% |
| 2024-06-30 | $108.73 Million | +373.76% |
| 2023-06-30 | $22.95 Million | +181.55% |
| 2022-06-30 | $8.15 Million | -60.81% |
| 2021-06-30 | $20.80 Million | -12.00% |
| 2020-06-30 | $23.64 Million | +3742.03% |
| 2019-06-30 | $615.22K | -96.22% |
| 2018-06-30 | $16.28 Million | +199.53% |
| 2017-06-30 | $5.44 Million | +70.92% |
| 2016-06-30 | $3.18 Million | +158.83% |
| 2015-06-30 | $1.23 Million | -45.22% |
| 2014-06-30 | $2.24 Million | +189.70% |
| 2013-06-30 | $-2.50 Million | -7.18% |
| 2012-06-30 | $-2.33 Million | -4.59% |
| 2011-06-30 | $-2.23 Million | -24.19% |
| 2010-06-30 | $-1.80 Million | -304.69% |
| 2009-06-30 | $877.74K | -31.75% |
| 2008-06-30 | $1.29 Million | -55.60% |
| 2007-06-30 | $2.90 Million | +30.25% |
| 2006-06-30 | $2.22 Million | -35.66% |
| 2005-06-30 | $3.46 Million | +54.00% |
| 2004-06-30 | $2.24 Million | -15.26% |
| 2003-06-30 | $2.65 Million | -34.56% |
| 2002-06-30 | $4.05 Million | -28.93% |
| 2001-06-30 | $5.69 Million | +10.57% |
| 2000-06-30 | $5.15 Million | -36.29% |
| 1999-06-30 | $8.08 Million | -48.68% |
| 1998-06-30 | $15.75 Million | -50.85% |
| 1997-06-30 | $32.05 Million | -15.47% |
| 1996-06-30 | $37.91 Million | -1.37% |
| 1995-06-30 | $38.44 Million | +47.60% |
| 1994-06-30 | $26.04 Million | +41.96% |
| 1993-06-30 | $18.35 Million | +60.85% |
| 1992-06-30 | $11.41 Million | -11.41% |
| 1991-06-30 | $12.88 Million | +7.64% |
| 1990-06-30 | $11.96 Million | -2.32% |
| 1989-06-30 | $12.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Botanix Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28450.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $226.30 Million | 278.36% |
| Other Comprehensive Income | $32.18 Million | 39.59% |
| Total Equity | $81.30 Million | 100.00% |
Botanix Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Botanix Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Advantage Solutions Inc
NASDAQ:ADV
|
$109.73 Million |
|
Parker Drilling Company
PINK:PKDC
|
$109.74 Million |
|
Shenzhen Breo Technology Co. Ltd. A
SHG:688793
|
$109.75 Million |
|
Tonnellerie Francois Freres SA
PA:TFF
|
$109.75 Million |
|
Eclat Forever Machinery Co., Ltd.
TWO:3485
|
$109.71 Million |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
$109.70 Million |
|
Hercules Metals Corp.
V:BIG
|
$109.67 Million |
|
Advanced Information Technology Public Company Limited
BK:AIT
|
$109.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Botanix Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 108,732,549 to 81,298,929, a change of -27,433,620 (-25.2%).
- Net loss of 86,396,186 reduced equity.
- Share repurchases of 2,538,675 reduced equity.
- New share issuances of 40,462,000 increased equity.
- Other comprehensive income increased equity by 20,980,909.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-86.40 Million | -106.27% |
| Share Repurchases | $2.54 Million | -3.12% |
| Share Issuances | $40.46 Million | +49.77% |
| Other Comprehensive Income | $20.98 Million | +25.81% |
| Other Changes | $58.33K | +0.07% |
| Total Change | $- | -25.23% |
Book Value vs Market Value Analysis
This analysis compares Botanix Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 5.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | $1214.29 | $0.25 | x |
| 1990-06-30 | $1182.36 | $0.25 | x |
| 1991-06-30 | $1273.19 | $0.25 | x |
| 1992-06-30 | $1156.21 | $0.25 | x |
| 1993-06-30 | $1293.72 | $0.25 | x |
| 1994-06-30 | $1589.58 | $0.25 | x |
| 1995-06-30 | $2206.73 | $0.25 | x |
| 1996-06-30 | $1739.70 | $0.25 | x |
| 1997-06-30 | $1281.17 | $0.25 | x |
| 1998-06-30 | $633.15 | $0.25 | x |
| 1999-06-30 | $323.19 | $0.25 | x |
| 2000-06-30 | $183.63 | $0.25 | x |
| 2001-06-30 | $182.97 | $0.25 | x |
| 2002-06-30 | $127.41 | $0.25 | x |
| 2003-06-30 | $85.61 | $0.25 | x |
| 2004-06-30 | $66.35 | $0.25 | x |
| 2005-06-30 | $11.16 | $0.25 | x |
| 2006-06-30 | $5.35 | $0.25 | x |
| 2007-06-30 | $6.20 | $0.25 | x |
| 2008-06-30 | $2.46 | $0.25 | x |
| 2009-06-30 | $1.54 | $0.25 | x |
| 2010-06-30 | $-2.84 | $0.25 | x |
| 2011-06-30 | $-3.32 | $0.25 | x |
| 2012-06-30 | $-2.21 | $0.25 | x |
| 2013-06-30 | $-0.58 | $0.25 | x |
| 2014-06-30 | $0.05 | $0.25 | x |
| 2015-06-30 | $0.01 | $0.25 | x |
| 2016-06-30 | $0.02 | $0.25 | x |
| 2017-06-30 | $0.01 | $0.25 | x |
| 2018-06-30 | $0.03 | $0.25 | x |
| 2019-06-30 | $0.00 | $0.25 | x |
| 2020-06-30 | $0.03 | $0.25 | x |
| 2021-06-30 | $0.02 | $0.25 | x |
| 2022-06-30 | $0.01 | $0.25 | x |
| 2023-06-30 | $0.02 | $0.25 | x |
| 2024-06-30 | $0.07 | $0.25 | x |
| 2025-06-30 | $0.04 | $0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Botanix Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1500.65%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.59x
- Recent ROE (-106.27%) is above the historical average (-129.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -0.60% | -0.38% | 0.79x | 2.01x | $-1.27 Million |
| 1990 | -0.76% | -0.42% | 0.82x | 2.19x | $-1.26 Million |
| 1991 | -0.49% | -0.24% | 0.93x | 2.18x | $-1.32 Million |
| 1993 | -6.98% | -2.72% | 0.87x | 2.95x | $-2.19 Million |
| 1994 | -7.29% | -3.17% | 0.93x | 2.48x | $-3.39 Million |
| 1995 | -0.63% | -0.35% | 0.98x | 1.84x | $-3.94 Million |
| 1997 | 0.41% | 0.33% | 0.81x | 1.57x | $-3.07 Million |
| 1998 | 0.54% | 0.00% | 0.00x | 1.92x | $-1.50 Million |
| 1999 | -1.05% | 0.00% | 0.00x | 2.00x | $-893.40K |
| 2000 | -61.59% | 0.00% | 0.00x | 1.02x | $-3.69 Million |
| 2001 | -6.20% | 0.00% | 0.00x | 1.03x | $-922.45K |
| 2002 | -34.84% | -382.11% | 0.08x | 1.11x | $-1.81 Million |
| 2003 | -52.82% | -151.24% | 0.31x | 1.11x | $-1.66 Million |
| 2004 | -42.68% | -209.17% | 0.19x | 1.08x | $-1.18 Million |
| 2005 | 0.06% | 242.82% | 0.00x | 1.07x | $-340.92K |
| 2006 | -125.85% | 0.00% | 0.00x | 1.13x | $-3.02 Million |
| 2007 | -117.96% | 0.00% | 0.00x | 1.21x | $-3.71 Million |
| 2008 | -219.68% | 0.00% | 0.00x | 1.84x | $-2.95 Million |
| 2009 | -346.74% | 0.00% | 0.00x | 2.30x | $-3.13 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.81 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.30 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.33 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.60 Million |
| 2014 | -50.41% | 0.00% | 0.00x | 1.14x | $-1.36 Million |
| 2015 | -82.55% | 0.00% | 0.00x | 1.07x | $-1.14 Million |
| 2016 | -53.71% | 0.00% | 0.00x | 1.16x | $-2.03 Million |
| 2017 | -87.79% | 0.00% | 0.00x | 1.09x | $-5.32 Million |
| 2018 | -67.62% | -619.37% | 0.10x | 1.09x | $-12.64 Million |
| 2019 | -2769.64% | -363.63% | 0.90x | 8.45x | $-17.10 Million |
| 2020 | -70.78% | -220.90% | 0.30x | 1.07x | $-19.09 Million |
| 2021 | -16.03% | -48.41% | 0.31x | 1.06x | $-5.41 Million |
| 2022 | -161.57% | -478.10% | 0.20x | 1.72x | $-13.99 Million |
| 2023 | -39.88% | -242.66% | 0.15x | 1.08x | $-11.45 Million |
| 2024 | -12.76% | -670.20% | 0.02x | 1.03x | $-24.74 Million |
| 2025 | -106.27% | -1500.65% | 0.04x | 1.59x | $-94.53 Million |
Industry Comparison
This section compares Botanix Pharmaceuticals Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Botanix Pharmaceuticals Limited (BXPHF) | $81.30 Million | -0.60% | 0.59x | $109.73 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |